Skyhawk Therapeutics Welcomes Aaron Deves as Chief Commercial Officer to Drive SKY-0515 Launch for Huntington's Disease
Skyhawk Therapeutics, a pioneering biotechnology firm focused on developing innovative therapies aimed at treating severe neurological diseases, has announced the appointment of Aaron Deves as the new Chief Commercial Officer. With over 30 years of experience in launching treatments for neurological disorders, including Huntington's disease, Deves is expected to play a vital role in steering the commercialization efforts for SKY-0515, a potential game-changing therapy targeted at this challenging condition.
Skyhawk Therapeutics is currently advancing its lead program, SKY-0515, through clinical development stages, aiming to provide a disease-modifying treatment for patients battling Huntington's disease. Bill Haney, CEO of Skyhawk, highlighted the importance of Deves's vast experience in building successful commercial teams and bringing innovative neurological treatments to market. He stated, "Aaron’s extensive background will enhance our capacity to deliver this much-needed therapy to patients swiftly, pending clinical results and regulatory approvals."
According to projections, Skyhawk may receive accelerated approval for SKY-0515 in Australia within the coming year, with expectations for registration in additional significant markets throughout 2027. Deves expressed his enthusiasm about joining Skyhawk, noting that the company's Huntington's disease program could become the cornerstone of a robust neuro business. He praised the company’s comprehensive pipeline of RNA-targeting drug programs, emphasizing their focus on creating small molecules that are more aligned with patient-friendly therapeutic options.
Before joining Skyhawk, Deves held senior leadership positions at Teva Pharmaceuticals, where he was instrumental in leading various commercial initiatives for specialty drugs, including AUSTEDO®, a treatment for chorea associated with Huntington's disease. His previous roles at Otsuka Pharmaceuticals and Pfizer equipped him with necessary skills to drive marketing and strategic direction for neuroscience portfolios involving both established and emerging therapies aimed at neurological conditions.
Tracing his roots back to Pfizer, where he dedicated 16 years in various progressive positions ranging from marketing to global development, Deves is well-prepared for the challenges posed in the biotechnology landscape. Holding a Bachelor of Science degree in Business Administration and Marketing from Columbia College, he combines a solid educational foundation with extensive work experience.
Skyhawk's proprietary platform, SKYSTAR®, is designed to discover and develop small molecule RNA modulating therapies that tackle some of the most difficult diseases, which demonstrates the company's commitment to addressing unmet medical needs in the field of neurology. As the launch date for SKY-0515 approaches, the organization is focused on ensuring that patients can access this crucial treatment as soon as possible.
In summary, Aaron Deves's appointment as Chief Commercial Officer marks a significant step forward for Skyhawk Therapeutics as it gears up for a potential breakthrough in the treatment landscape for Huntington's disease. The collective expertise of Deves and the Skyhawk team positions the company for success as it navigates the complexities of regulatory approvals and market entry strategies, striving to make a meaningful difference in the lives of those impacted by this devastating condition.
Skyhawk Therapeutics is currently advancing its lead program, SKY-0515, through clinical development stages, aiming to provide a disease-modifying treatment for patients battling Huntington's disease. Bill Haney, CEO of Skyhawk, highlighted the importance of Deves's vast experience in building successful commercial teams and bringing innovative neurological treatments to market. He stated, "Aaron’s extensive background will enhance our capacity to deliver this much-needed therapy to patients swiftly, pending clinical results and regulatory approvals."
According to projections, Skyhawk may receive accelerated approval for SKY-0515 in Australia within the coming year, with expectations for registration in additional significant markets throughout 2027. Deves expressed his enthusiasm about joining Skyhawk, noting that the company's Huntington's disease program could become the cornerstone of a robust neuro business. He praised the company’s comprehensive pipeline of RNA-targeting drug programs, emphasizing their focus on creating small molecules that are more aligned with patient-friendly therapeutic options.
Before joining Skyhawk, Deves held senior leadership positions at Teva Pharmaceuticals, where he was instrumental in leading various commercial initiatives for specialty drugs, including AUSTEDO®, a treatment for chorea associated with Huntington's disease. His previous roles at Otsuka Pharmaceuticals and Pfizer equipped him with necessary skills to drive marketing and strategic direction for neuroscience portfolios involving both established and emerging therapies aimed at neurological conditions.
Tracing his roots back to Pfizer, where he dedicated 16 years in various progressive positions ranging from marketing to global development, Deves is well-prepared for the challenges posed in the biotechnology landscape. Holding a Bachelor of Science degree in Business Administration and Marketing from Columbia College, he combines a solid educational foundation with extensive work experience.
Skyhawk's proprietary platform, SKYSTAR®, is designed to discover and develop small molecule RNA modulating therapies that tackle some of the most difficult diseases, which demonstrates the company's commitment to addressing unmet medical needs in the field of neurology. As the launch date for SKY-0515 approaches, the organization is focused on ensuring that patients can access this crucial treatment as soon as possible.
In summary, Aaron Deves's appointment as Chief Commercial Officer marks a significant step forward for Skyhawk Therapeutics as it gears up for a potential breakthrough in the treatment landscape for Huntington's disease. The collective expertise of Deves and the Skyhawk team positions the company for success as it navigates the complexities of regulatory approvals and market entry strategies, striving to make a meaningful difference in the lives of those impacted by this devastating condition.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.